BioSpace News Archive

Protalix BioTherapeutics, Inc. announced that it received, on September 3, 2020, notification from the NYSE American LLC that the Company has regained compliance with all of the continued listing standards set forth in Part 10 of the NYSE American Company Guide.

AIM ImmunoTech Inc., announced that Thomas K. Equels, CEO of AIM ImmunoTech, will participate in a virtual panel titled, “New Approaches to COVID-19: Hidden Breakthroughs,” being held on Thursday, September 10, 2020 at 1:00 p.m. ET.

Evelo Biosciences, Inc., a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, announced that management will participate in two upcoming virtual investor conferences in September

The first study to report on convalescent plasma in life-threatening cases of the virus makes the case for a larger, randomized trial

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced that it will participate in the following investor conferences:

HTG Molecular Diagnostics, Inc., a diagnostic company whose mission is to advance precision medicine, announced John Lubniewski, President and CEO of HTG, will present virtually at the H.C. Wainwright 22nd Annual Global Investment Conference and at the Cantor Fitzgerald Global Healthcare Conference.

Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, announced that the Company will participate in the following upcoming investor conferences.

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that Frank Bedu-Addo, CEO of PDS Biotech, will present virtually at the H.C. Wainwright & Co.

Annexon, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, announced second quarter 2020 financial results and recent highlights.

TTI-622 (SIRPa-IgG4 Fc) completed 8 mg/kg safety assessment in the ongoing dose escalation study in relapsed/refractory lymphoma; now escalating to 12 mg/kg dose level.